The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updates to NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
 
Charles D. Lopez
Research Funding - Roche/Genentech (Inst); Taiho Pharmaceutical
 
Adel Kardosh
Consulting or Advisory Role - Astellas Pharma; Astex Pharmaceuticals; Eisai; Exelixis; Exelixis; Genentech
Research Funding - Natera
 
Emerson Yu-sheng Chen
Other Relationship - Horizon CME; Taiho Pharmaceutical
 
Guillaume Joe Pegna
Stock and Other Ownership Interests - Amryt Pharma
 
Skye C. Mayo
No Relationships to Disclose
 
Robert Eil
No Relationships to Disclose
 
Erin W. Gilbert
No Relationships to Disclose
 
Flavio G. Rocha
Consulting or Advisory Role - Medtronic
Research Funding - Gunze
Travel, Accommodations, Expenses - Lynx Group
 
Nima Nabavizadeh
No Relationships to Disclose
 
Aaron Grossberg
Consulting or Advisory Role - Endevica Bio
 
Alexander Guimaraes
Honoraria - Agfa Healthcare
Consulting or Advisory Role - BioClinica; Calyx; Merck; Takeda
Expert Testimony - Witherspoon Kelly
 
Bryan Foster
No Relationships to Disclose
 
Brian Brinkerhoff
No Relationships to Disclose
 
Shaun Goodyear
Consulting or Advisory Role - PDX Pharmacy
 
Dove Keith
No Relationships to Disclose
 
Gordon B. Mills
Stock and Other Ownership Interests - Catena; ImmunoMET; SignalChem; Tarveda Therapeutics; Turbine
Consulting or Advisory Role - AstraZeneca; BlueDot; Chrysalis Biotherapeutics; Ellipses Pharma; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Lilly; MedaCorp; NanoString Technologies; PDX Pharmacy; SignalChem; Tarveda Therapeutics; Turbine; Zentalis
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Genentech; GlaxoSmithKline; Komipharm; Lilly; NanoString Technologies; Ovarian Cancer Research Foundation; Prospect Creek Foundation
Patents, Royalties, Other Intellectual Property - Myriad Genetics; NanoString Technologies
 
Rosalie C. Sears
Consulting or Advisory Role - Larkspur; Novartis; Rappta Therapeutics
Research Funding - Cardiff Oncology (Inst)
Travel, Accommodations, Expenses - Rappta Therapeutics
 
Jonathan Brody
No Relationships to Disclose
 
Brett C. Sheppard
No Relationships to Disclose